Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasus Lymphoma 205
2021-002150-91Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegenzileukin and pembrolizumab in mature B-cell lymphoma and classical Hodgkin lymphoma (cHL) (2 cohorts), sponsored by Sanofi. Primary endpoint: Complete Response Rate for Cohort A. Started Dec 2021; status: terminated.
02
Drugs
pegenzileukinpembrolizumab
03
Conditions
mature B-cell lymphomaclassical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2021-002150-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002150-91.